Angus Jeffrey

Angus Jeffrey is a medical researcher and Gastroenterology and Hepatology Advanced Trainee at Sir Charles Gairdner Hospital, affiliated with the University of Western Australia Medical School. Holding both MD and PhD qualifications, his work focuses on inflammatory bowel disease, liver transplantation outcomes, and fibrosis assessment methodologies. His research directly contributes to UN Sustainable Development Goals related to good health and well-being.

Jeffrey's research interests center on gastrointestinal disorders, particularly inflammatory bowel disease management and liver disease progression. His work examines treatment persistence with biologics like infliximab, prognostic scoring systems for liver cirrhosis, and diagnostic accuracy of fibrosis assessment tools. He has made significant contributions to understanding remission patterns in inflammatory bowel disease and graft survival metrics in liver transplantation.

His publication record demonstrates a clear trend toward improving clinical decision-making in hepatology and gastroenterology through evidence-based scoring systems and treatment evaluation. Recent work focuses on validating diagnostic tools like the AGILE 3+ score for fibrosis assessment and examining long-term outcomes of biosimilar switches in inflammatory bowel disease therapy.

Jeffrey actively collaborates with leading researchers in hepatology including Adams, Calzadilla-Bertot, and Wallace, contributing to multicenter studies that advance clinical practice in liver disease management. His work appears in high-impact journals including Journal of Gastroenterology and Hepatology, Hepatology, and Alimentary Pharmacology and Therapeutics.